Compounding pharmacists from across America will be on Capitol Hill in Washington, D.C. next Tuesday, May 21 to ask Congress to act to preserve patient access to compounded medications. You can help tee-up our conversations with members of Congress by sending a message to your members of Congress NOW.
The “National Academies of Sciences, Engineering and Medicine Health and Medicine Division” has announced1 an investigation titled Clinical Utility of Treating Patients with Compounded “Bioidentical Hormone Replacement Therapy”. The fact that this written title describing the investigation has quotation marks only around “Bioidentical Hormone Replacement Therapy” gives us a very large clue that from the start this investigation will be biased, as it can’t bring itself to fully recognize the name that has been used by physicians and the millions of individuals using this treatment since the 1980s.
PCCA members will be in D.C., April 9-10, for the 7th Annual ACT Legislative Conference, calling on lawmakers to support patient access to compounded medications. If you can’t join us at ACT, we need your help in contacting your Representatives now on these 2 opportunities to help patients. Please review the following information and contact your Congressional Representatives’ offices now.
On March 20th, the AANP filed a Citizen’s Petition with the FDA as the next step in challenging the FDA’s unprecedented attack on physician-prescribed compounded nutrients which is on track to reject fully 95 percent of the 300+ nominated natural ingredients often used by patients as compounded medications.
In a considerable win for patients who need compounded medications, the International Academy of Compounding Pharmacists (IACP), working with the DQSA Coalition, is very pleased to announce that the President has signed the Congressional Omnibus bill into law, H.R. 244, which provides funding through September 30, 2017, and includes language that addresses the Memorandum of Understanding, office-use, and pharmacy inspections.
Marie Antoinette’s quote is a great reminder that at times, new uses can be found with old things, such is the case with the drug Naltrexone. First synthesized as a competitive opioid antagonist in 1963, for many years research on Naltrexone remained dormant until